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Abstract The X-ray structure of the N-terminal truncated hu-
man apoA-I [Borhani et al., Proc. Natl. Acad. Sci. USA 94
(1997) 12291] and the NMR structure of intact human apoA-I
[Okon et al., FEBS Lett. 517 (2002) 139] found similar repeat-
ing helices. The crystal structure is a twisted circular four-helix
bundle, consisting of four molecules of apoA-I(44^243), where
four copies of the lecithin:cholesterol acyltransferase (LCAT)-
activating domains are located outside the ring structure, while
the aromatic-rich strong lipid-binding domains are inside. This
architecture suggests a lipid-binding mechanism that lipids di-
rectly enter the hole of the crystal structure. Indeed, four copies
of Trp50 and Trp72 are exposed and oriented toward the center
of the ring, initiating lipid binding. This is followed by the in-
side^out rotations of the terminal helices to make a belt with all
the hydrophobic faces of the helices facing inward. Such lipid-
binding induced rotations have an impact on the conformation of
the lipid-free form. Indeed, the structure of residues 78^81
changes from helical (free) to disordered (bound) while the
structure of residues 221^227 changes from extended to helical.
: 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Human apoA-I is the major player in reverse cholesterol
transport
It is well established that high-density lipoproteins (HDL)
have a protective e¡ect against atherosclerosis [1]. The protec-
tive e¡ect of HDL is attributed to the reverse cholesterol
transport pathway. This pathway includes cholesterol e¥ux
from the tissue surface, esteri¢cation of free cholesterol by
lecithin:cholesterol acyltransferase (LCAT), followed by deliv-
ering HDL back to the liver to be degraded [2]. The most
abundant protein of HDL is apoA-I, which is the major play-
er in the arena of reverse cholesterol transport. As a conse-
quence, one of the approaches in antiatherogenic drug design
is to mimic human apoA-I. It is, therefore, to our bene¢t to
understand the structure and function of HDL, especially
apoA-I.
The primary structure of 243-residue [3] apoA-I contains
multiple 11- and 22-amino acid-residue repeating units [4].
These repeats were proposed to form amphipathic helices
that are responsible for lipid binding [5,6]. Based on site-di-
rected mutagenesis and synthetic peptide studies, the LCAT-
activating domain of apoA-I has been mapped to residues
144^185 [7^10], whereas the N- and C-terminal regions are
recognized as strong lipid-binding domains [11^13]. An
N-terminal truncated apoA-I, namely, apoA-I(44^243), shares
similar properties with intact apoA-I. Like intact apoA-I,
apoA-I(44^243) shows no di¡erence in binding lipids [14],
and can form mature spherical HDL particles [15], supporting
the concept that residues 1^43 constitute an independent do-
main. Further, signi¢cant progress has been made in the elu-
cidation of the three-dimensional structure of human apoA-I
[14,16^20]. The structure of apoA-I(44^243), elucidated by
X-ray di¡raction analysis in the absence of lipids, contains
10 helices [14], whereas the structure of intact apoA-I, deter-
mined in the lipid-mimetic micelles, contains 11 helices [19].
Based on the crystal structure, models for the discoidal [14,21]
and spherical [14] HDL particles have both been proposed as
belts wrapping around phospholipids.
The structural conversion from the lipid-free apoA-I to dis-
coidal and spherical HDL particles is of fundamental signi¢-
cance in understanding the key process of reverse cholesterol
transport. The molecular basis for such a structural conver-
sion of apoA-I is not yet understood, although an open model
has been proposed for the single-chain up-and-down helix-
bundle structures by hinge rotation of a pair of helices by
180‡ for lipid binding [22^24]. This article proposes a novel
mechanism for the structural conversion of apoA-I(44^243)
from the free to lipid-bound form based on current structural
data available for human apoA-I [14,17^20]. Since there is no
high-resolution structure for the full-length lipid-free apoA-I,
the possible mechanisms for its lipid binding are not discussed
in this article.
2. The structures of human apoA-I(44^243) in the crystal
and intact apoA-I in micelles are remarkably similar
Direct structural analysis of the heterogeneous lipoprotein
particles by either high-resolution NMR spectroscopy or
X-ray crystallography is still a challenging problem. The crys-
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tal structure of apoA-I(44^243) was solved in the absence of
lipids [14]. On the other hand, NMR structures were eluci-
dated in micelles (V50 AN ) of dodecyl phosphocholine or so-
dium dodecyl sulfate, which mimic the lipid environment of
the smallest HDL [17^20,25]. Similar helical structures were
identi¢ed for the common region by X-ray crystallography for
apoA-I(44^243) [14] (Fig. 1A) and by NMR spectroscopy for
intact apoA-I [19] (Fig. 1B). Also, NMR analysis on the full-
length apoA-I identi¢ed an additional helix, residues 8^32, at
the N-terminal domain. The fact that 13 disordered residues
separate the N-terminal helix (H0) from helix 1 (H1) supports
the concept that the N-terminal domain of apoA-I, residues
1^43, functions as an independent domain. Human apoA-I
structure is characterized by the modular nature as predicted
from the amino acid sequence [5,6]. A typical structural mod-
ule is the helix^hinge^helix motif [17]. This structure, origi-
nally found in apoA-I(142^187), is maintained in apoA-I(122^
187), apoA-I(1^186) and intact apoA-I [17^19]. The structural
units found in apoA-I(1^186) [18] recur in intact apoA-I [19].
The modular structure is also demonstrated by human apoC-I
in a series of structural analyses from peptide fragments to
intact protein [20,26]. A notable feature of this curved helix^
hinge^helix structural motif is that hydrophobic residues oc-
cupy the same concave surface. Interestingly, a similar struc-
ture, including the same hydrophobic packing between Pro165
and Tyr166 in the hinge, was found in apoA-I(44^243) in the
crystal [14]. In micelles, this structural motif interacts with
lipids as con¢rmed by NMR using intermolecular NOESY
experiments [17,25]. In the crystal, this structural motif inter-
acts with three other apoA-I chains of the four-helix bundle.
In addition to helices H6 and H7, the three-dimensional struc-
tures for helices H1^H3 (residues 50^101) are also strikingly
similar in the crystal and micelles [20]. Hence, we conclude
that the structural similarities of human apoA-I in the absence
and presence of lipids are convincingly high, at least at the
level of the secondary structure (Fig. 1).
This being said, some key structural di¡erences in the two
environments are worth pointing out. While a kink was ob-
served at the proline residues in the crystal [14], NMR studies
of apoA-I fragments and intact apoA-I in the micelles suggest
two to ¢ve hinge residues between the repeating helices
(Fig. 1B). These multiple ‘hinges’ in apoA-I are believed to
be crucial for the plasticity of apoA-I, allowing it to adapt to
HDL particles of a variety of di¡erent sizes and shapes [17^
20]. Except for the end e¡ect, other major structural di¡er-
ences lie in regions 78^81 and 221^227. In the crystal, residues
78^81 are helical while residues 221^227 are extended [14]. In
contrast, residues 78^81 become disordered whereas residues
221^227 are helical in micelles [19].
3. The functional domains of apoA-I have distinct locations in
the crystal structure
To see the location of the LCAT-activating domain in the
crystal structure of apoA-I(44^243), helices H6 and H7 are
represented in the space-¢lling model in a circular view of
the crystal structure (Fig. 2A) [14]. Surprisingly, all four cop-
ies of the LCAT-activating domains are located outside of the
tetrameric ring structure. In contrast, the strong lipid-binding
domains, at the N- and C-termini of apoA-I(44^243), are
located in the inner ring (Fig. 2A). Previous work on the
LCAT-activating domain of apoA-I found that the amino
acid sequence for that region is characterized by richness in
arginines, lack in aromatic residues, and no hydrophobic pairs
with (I, I+1) relationship in the sequence [17]. This is a weak
lipid-binding region [13]. What will be the typical feature of
those strong lipid-binding regions?
Fig. 1. NMR and X-ray structural comparison of apoA-I. Second-
ary structures of human apoA-I(44^243) (A) determined by X-ray
crystallography in the lipid-free state [14] and intact human apoA-I
(B) determined by NMR spectroscopy in SDS micelles [19]. Helices,
represented by boxes, are labeled from H0 to H10 to be consistent
with the convention in literature. Helical regions in apoA-I identi-
¢ed by X-ray (NMR) studies are H0, (8^32); H1, 50^65 (45^64);
H2, 66^87 (67^77 and 82^86); H3, 88^98 (90^97); H4, 99^120 (100^
118); H5, 121^142 (122^140); H6, 143^164 (146^162); H7, 165^186
(167^186); H8, 187^208 (187^205); H9, 209^219 (210^216); and
H10, 228^243 (221^239). In micelles (B), H2 is split by a non-helical
segment, residues 78^81, and residues 221^227 are helical (indicated
by arrows). Strong lipid-binding helices are labeled with LP and the
helices that activate LCAT are labeled with LCAT (reviewed in
Ref. [13]). Aromatic-residue-rich regions, identi¢ed in this work, are
represented by solid squares and labeled as aromatic (refer to
Fig. 3A).
Fig. 2. Distinct locations of the functional domains of apoA-I in
the circular views of the tetrameric crystal structure. A: Four copies
of the LCAT-activating domain, residues 142^187, represented in
the space-¢lling models (gray), occupy the outer circles of the dis-
torted ring structure. The four apoA-I(44^243) chains (a^d) as well
as the N-, and C-termini of the chain in the crystal structure are la-
beled. B: The strong lipid-binding domains rich in aromatic residues
occupy the inner circles of the distorted ring structure. Residues 49^
73, 98^116, and 224^237 are represented in the space-¢lling (gray,
but the Trp residues in dark), ribbon (black), and backbone stick
(black) models, respectively. For each of the aromatic-rich regions,
only two copies are labeled by arrows due to symmetry. The PDB
accession code for apoA-I(44^243) is 1av1 [14]. Figures were made
using RasMol (http://www.umass.edu/microbio/rasmol).
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3.1. The strong lipid-binding regions are rich in aromatic
residues
In Fig. 3A, a monomer of apoA-I(44^243) from the crystal
is shown with aromatic residues, Trp, Phe and Tyr, repre-
sented in the space-¢lling model. Interestingly, these aromatic
residues in the sequence are mainly clustered in three regions:
residues 49^73 (4), 98^116 (4) and 224^237 (3), where the
number of aromatic residues for each region is indicated in
the parentheses. These aromatic-rich regions are predomi-
nantly located in the inner ring of the structure (Fig. 2B).
On the other hand, lipid-binding studies identi¢ed residues
44^65, 100^121 and 210^241 as important lipid-binding re-
gions [10^13,27]. Clearly, the three key lipid-binding regions
in apoA-I correlate well with the three aromatic-rich regions
found here (Fig. 1A), indicating that aromatic residues play
an essential role in binding lipids. The NMR studies [20] in-
dicate that helices H1 and H2 are essentially continual, sup-
porting the current identi¢cation of the ¢rst aromatic-rich
region as one of the important lipid-binding units. Earlier
structural studies of apoE [28] and apoC-I [26] by NMR
also pointed to the importance of aromatic residues in anchor-
ing apolipoproteins to lipid micelles. These observations are
consistent with the hydrophobicity scale analysis for mem-
brane proteins that aromatic residues are especially favored
at the interface [29]. A recent interesting study on an apoA-I-
mimicking peptide showed that the property of the peptide
alters with the addition of Phe residues to the hydrophobic
face. Many biophysical and biochemical properties become
optimal when four to ¢ve Phe residues are included [30].
This ‘in vitro evolution’ result is remarkably similar to the
three to four aromatic residues found here in the aromatic-
rich regions of apoA-I designed by nature for our best bene¢t.
3.2. Aromatic-aromatic interactions stabilize the lipid-free
apoA-I(44^243) structure
Being prompted by the interesting ¢nding above, we also
looked into the distribution of aromatic residues in the entire
tetrameric crystal structure of apoA-I(44^243). All Phe and
Trp aromatic side chains are located in the inner ring of the
structure, although the distribution of the Tyr residue varies
(Fig. 3B). In the structure, these aromatic residues actually
interact with each other. Two Tyr192 (chains b and c) pack
with two Phe71 (chains a and d), forming a hydrophobic
cluster (Fig. 3B). Starting from Tyr166, a train of aromatic
residues, including Tyr100, Phe104, Trp108, Tyr115, Phe225,
Phe229 and Tyr236, pack against one another. Two Tyr236
from chains a and b, or chains c and d, also stack together,
consistent with an earlier report that the C-terminal domain
of apoA-I plays a key role in protein aggregation [12]. Sim-
ilarly, the aromatic-rich C-termini of apoE [31] and apoC-I
[32], known to be important in lipid binding, are also essential
for apolipoprotein aggregation. Hence, aromatic^aromatic in-
Fig. 3. Distribution of the aromatic residues of apoA-I(44^243) in the crystal structure of the (A) monomeric and (B) tetrameric forms. The
aromatic residues are shown in the space-¢lling model. Color code: backbones in green, Trp in red, Phe in yellow, and Tyr in magenta. The
arrows indicate one of the symmetry axes of the circular structure and also indicate the positions for the stacking Tyr236 at the C-terminus
of apoA-I. Note that Trp50 and Trp72 are exposed on the inner curved surface of the structure (labeled with the single-letter amino acid code).
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teractions [33] play a key role in apolipoprotein aggregation
and in the stabilization of the helix-bundle structure of apoA-
I(44^243). In strong contrast, eight Trp50 and Trp72, two
from each chain, are exposed on the inner surface of the
ring structure of apoA-I(44^243) and not involved in aromatic
packing (Figs. 2B and 3B).
Before moving on further, it is pertinent to mention the
resolution of the structure. The structure of lipid-free apoA-
I(44^243) was originally solved at 4 AN and further re¢ned to
3 AN using data collected at the synchrotron source. Further
structural re¢nement did not make much di¡erence. Because
of the strong electron density of the aromatic rings and me-
thionine residues, they have been useful in tracing the direc-
tion of the chains of apoA-I in the crystal [14]. Hence, the
positions of aromatic side chains in the crystal are reasonably
well determined with a con¢dence in M1 angle greater than
75%. Also, the M2 angles of Trp are pretty well de¢ned be-
cause of the high electron density although the M2 angles of
Tyr and Phe are not as certain (D. Borhani, personal commu-
nication).
4. A model for the structural conversion of human
apoA-I(44^243) from the free to lipid-bound form
The crystal structure of apoA-I(44^243) is a lipid-free form
[14], while the NMR structure is the conformation of the
monomeric apoA-I in micelles [19]. Assume that the micelle-
associated conformation of apoA-I represents the lipid-bound
form. This raises the question of how the helix-bundle struc-
ture of apoA-I(44^243) converts from the free to the lipid-
bound state. A previous study on lipid binding of apoA-
I(166^185), apoA-I(142^187) and apoA-I(122^187) revealed
two mechanisms [17,25]. Lipid binding can be initiated either
by electrostatic interactions between cationic side chains
(mainly Arg) of these peptides and anionic lipids or by hydro-
phobic interactions between them, depending on the type of
lipids. Since phospholipids and cholesterol are predominant in
HDL with little anionic lipids, lipid binding of apoA-I(44^
243) is more likely to be initiated by hydrophobic interactions.
The observation that strong lipid-binding domains are
mainly located inside the tetrameric structure immediately
suggests an attractive model for the structural conversion.
In such a model, lipids are allowed to directly enter the hole
of the pre-formed circular structure of apoA-I(44^243) and
associate with the strong lipid-binding domains. A key ques-
tion will be where such a lipid binding commences. This is
puzzling since hydrophobic leucine and valine residues were
noticed to be buried in the hydrophobic core of the helix
bundle [14]. The analysis of the aromatic residues of apoA-
I(44^243) in Section 3 turned out to be informative. While all
the Phe and most of the Tyr residues are buried, it is exciting
to note that the side chains of the four copies of Trp50 and
Trp72 are actually exposed on the inner surface and oriented
toward the pseudo-center of the elliptical ring structure of
apoA-I(44^243) (Figs. 2B and 3B). In addition, close to
Trp50, Leu44 and Leu47 are partially exposed (not shown).
These exposed tryptophan regions are proposed to initiate
lipid binding of the truncated apoA-I. Lipid anchoring by
these exposed side chains can subsequently induce the struc-
tural re-arrangement of the protein to expose the buried hy-
drophobic surfaces for additional lipid binding. Because sim-
ilar amphipathic helical structures have been observed in the
lipid-free apoA-I(44^243) and lipid-bound intact apoA-I
(Fig. 1), the structural conversion to the lipid-bound state
may be achieved by simple terminal helix rotations around
the long helix axis. The inside^out rotations for both
C- and N-terminal strong lipid-binding helices are necessary
to bring the hydrophobic surfaces of all the amphipathic heli-
ces into the same face to facilitate the belt to wrap around the
lipid matrix as proposed in the belt model [14,21]. It is inevi-
table that such rotations will cause an increase or decrease in
helical turns in apoA-I(44^243) before and after lipid binding.
Indeed, there are structural di¡erences between the lipid-free
apoA-I(44^243) and lipid-bound apoA-I [14,19]. Upon lipid
binding, residues 78^81 at the N-terminus change conforma-
tion from helical in the crystal to disordered in micelles. In
contrast, residues 221^227 at the C-terminus change from ex-
tended in the crystal to helical in micelles (Fig. 1).
There are several lines of evidence supporting this model.
First, tryptophan side chains exposed on the protein surface
are hotspots for ligand binding [34]. These exposed Trp side
chains are thus excellent candidates for initial lipid binding of
apoA-I(44^243). Second, the side chains of tryptophans are
always well de¢ned in the micelle-bound structures of apoli-
poproteins and their segments [26,28], indicating the key role
of these rigid aromatic rings in anchoring lipids. Indeed, the
side-chain orientations of tryptophan in those apolipoprotein
structures determined in micelles are consistent with an earlier
¢nding of Landolt-Marticorena et al. [36] who showed that
tryptophan is almost always found at the membrane^water
interface, with the hydrophobic six-membered ring oriented
toward the hydrophobic face and polarizable imino group
intruding into the hydrophilic face. The locations of the three
aromatic-rich regions of apoA-I in the strong lipid-binding
domains are consistent with their role in binding lipids. The
aromatic-rich N- and C-terminal regions have been implicated
in the initial rapid lipid binding of apoA-I [10^12,16]. Third
and more importantly, both in vitro and in vivo experiments
[15] showed that further deletion of helix H1 from apoA-I(44^
243) blocks the formation of spherical HDL particles [13,15].
In contrast, both intact apoA-I and apoA-I(44^243) yielded
matured spherical HDL particles. Since the exposed Leu44,
Leu47 and Trp50 residues belong to helix H1, this failure in
structural conversion further reinforces the importance of
these residues in initiating lipid binding and subsequent mat-
uration of HDL. The structural conversion model proposed
here for the N-terminal truncated apoA-I can be tested by
site-directed mutagenesis. Whether this model applies to intact
lipid-free apoA-I [16,35] may also be tested similarly even in
the absence of a high-resolution structure.
In summary, the aromatic residues in apoA-I(44^243) have
been proposed to play a key role in stabilizing the helix-bun-
dle structure in the lipid-free state, in initiating lipid binding,
and in stabilizing the lipid-bound structures. The unique lipid-
binding mechanism proposed here for apoA-I(44^243) pro-
vides additional insight into the belt model [14,21]. It may
also be crucial for rapid cholesterol binding by apoA-I and,
thus, sheds light on the process of reverse cholesterol trans-
port.
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